Demand Media, Inc. DMD 深 滬
已收盤 10-08 16:00:00 美东时间
6.35
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 6.35
- 總市值 0
- 52周最高 6.35
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 4.41
- 委 比 0.00%
- 總股本 --
- 歷史最高 12.50
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3.62
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多每日全球并购：纽曼矿业考虑收购巴里克矿业旗下内华达州金矿资产 | 青岛啤酒终止收购即墨黄酒（10/27）
-每日资讯- 1、纽曼矿业考虑收购巴里克矿业旗下内华达州金矿资产 纽曼矿业正在考虑通过潜在交易，获得竞争对手巴里克矿业旗下内华达州金矿资产的控制权。纽曼矿业已持...
10-27 20:35
Avidity stock surges on $12B Novartis deal
Avidity Biosciences (NASDAQ:RNA) shares surged as much as 45% in premarket trading on Monday after Novartis (NYSE:NVS) agreed to buy the biotechnology company in a deal valued at $12 billion. Novartis...
10-27 16:35
诺华宣布将以约120亿美元收购美国生物科技公司
（来源：欧洲并购与投资） 诺华宣布将以约120亿美元收购美国生物科技公司 图片来源：iStock 在强生以146亿美元收购Intra-Cellula...
10-27 16:29
诺华120亿美元收购RNA疗法公司Avidity Biosciences
（来源：求实药社） 2025年126日，诺华宣布与部位于美国圣地亚哥的生物制药公司Avidity Biosciences达成最终收购协议。后者是一家...
10-27 12:03
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology program...
10-27 01:07
双十一选购指南：从技术到场景拆解海信激光电视
一年一度的双十一大促已经拉开帷幕，在平台优惠、商家让利、国补政策等多重因素推动下，双十一无疑已成为消费者换购电视的绝佳时机。对于喜欢追求高色域、高沉浸感以及健康...
10-24 12:32
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares
Keros Therapeutics (NASDAQ:KROS) has commenced a cash tender offer to repurchase up to $194.4 million of common shares, at a purchase price of $17.75 per share. The Company expects to fund the tender ...
10-20 18:26
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonuc...
10-16 21:00
Avidity reports positive pre-BLA meeting on Duchenne muscular dystrophy asset del-zota
Avidity Biosciences (NASDAQ:RNA) said that it will submit a BLA for its Duchenne muscular dystrophy candidate delpacibart zotadirsen (del-zota) in Q1 2026 following a pre-BLA meeting with the US FDA. ...
10-13 23:05
What's Going On Sarepta Stock On Wednesday?
Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.
10-08 23:19
